Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Short-term Investments (2020 - 2025)

10x Genomics (TXG) has disclosed Short-term Investments for 6 consecutive years, with $49.4 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments changed 0.22% to $49.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.4 million through Dec 2025, changed 0.22% year-over-year, with the annual reading at $49.4 million for FY2025, 0.22% changed from the prior year.
  • Short-term Investments hit $49.4 million in Q4 2025 for 10x Genomics, roughly flat from $49.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $225.5 million in Q2 2022 to a low of $27000.0 in Q1 2022.
  • Historically, Short-term Investments has averaged $39.5 million across 5 years, with a median of $23.8 million in 2021.
  • Biggest five-year swings in Short-term Investments: tumbled 99.95% in 2021 and later skyrocketed 318307.41% in 2023.
  • Year by year, Short-term Investments stood at $28000.0 in 2021, then skyrocketed by 9303.57% to $2.6 million in 2022, then skyrocketed by 1017.01% to $29.4 million in 2023, then surged by 67.74% to $49.3 million in 2024, then rose by 0.22% to $49.4 million in 2025.
  • Business Quant data shows Short-term Investments for TXG at $49.4 million in Q4 2025, $49.6 million in Q3 2025, and $49.5 million in Q2 2025.